Company Profile

Ubivac Is A Clinical Stage Biotech Engaged In Research And Developmentand Manufactureof Therapeutic Immune Activatorsvaccines And Cellular Immunotherapies To Combat Cancerused In Combination With Other Immunotherapiesubivac S Patented Technologies Have Proven Highly Effective At Improving Survival And Apparent Cure In Difficult To Treat Animal Cancerspmid27874054Pmid31747946Pmid22068657 Ubivac Believes That The Explanation For This Effectiveness Lies In Several High Impact Publications From 2021 Identifying A Previously Unknown Class Of Shared Non Mutated Cancer Neoantigens That Make Up As Much As 25Of The Antigens On Cancer Cellspmid33740418Pmid33691108Pmid34663921 As The Non Mutated Shared Cancer Neoantigens Are Short Lived Proteinsthe Majority Are Expected To Be Contained In Ubivac S Dpv 001Importantlythese Findings Help Explain Why Ubivac S Immunotherapy Provided Cross Protective Cancer Immunity In Preclinical Modelssomething That Had Not Been Observed In 50 Years Of Studypmid21810919 These Remarkable Studies Raised The Possibility Of Off The Shelf Universal Cancer Vaccinespmid33852826 Ubivac Has Completed An Nci Funded Phase I Ii Adjuvant Trial Of Its Lead Agentdpv 001This Trial Met Its Endpointsdetermined Safetyidentified Drug Formulationand Demonstrated Proof Of Conceptbased On These Data Ubivac Partnered With The Providence Cancer Institute And Incyte On A First In Human Immunotherapy Trial Of Ubivac S Dpv 001Anti Gitr And Anti Pd 1 For Advanced Hnsccthe First Patients Were Treated In Q4 2021And Preliminary Immunological Monitoring Data Will Be Presented At Aacr In April 2022Ubivac Also Has A Pipeline Of Cellular Therapies Under Developmentgiven That Ubivac S Ceo And Csotogetherhave 55Years Of Experience With Preclinical And Clinical Studies Of Adoptive Immunotherapyubivac Is Well Positioned To Bring Their Innovative Cellular Therapy Platforms To The Clinic